Physician

Eugenio Gerardo Galindo, M.D.

According to 2025 Medicare claims, Eugenio Galindo, M.D. (NPI: 1174599948) practices hematology/oncology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is MCALLEN ONCOLOGY PA (NPI: 1982711743; TIN: 742966092) and primary practice location at 78504-6595.

Galindo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 146 traditional Medicare patients, billed 104,751 HCPCS/CPT codes, and received $1,456,760 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,905 prescription claims across 353 beneficiaries totaling $20,450,154 in drug costs, led by Xtandi (Enzalutamide). DME data shows 28 claims. Open Payments data shows 161 records totaling $4,268. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $1,807,750 to $1,456,760. In contrast, Part D prescription costs have risen steadily, from $2,555,655 to $20,450,154. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $603 to $201.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	758	202,399	$1,807,750
2016	795	209,378	$2,436,626
2017	734	267,343	$2,215,477
2018	692	203,653	$2,432,481
2019	455	134,692	$1,941,011
2020	153	52,138	$761,303
2021	115	76,913	$1,199,220
2022	163	80,946	$1,275,574
2023	165	91,761	$1,096,236
2024	146	104,751	$1,456,760

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	451	3,072	$2,555,655
2016	489	3,304	$3,363,309
2017	564	3,741	$6,160,440
2018	707	4,788	$13,187,801
2019	561	3,258	$11,210,933
2020	183	1,637	$11,022,335
2021	143	1,533	$11,293,387
2022	257	1,837	$11,500,658
2023	339	3,822	$15,325,581
2024	353	4,905	$20,450,154

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	68	188	$44,598
2016	77	122	$15,107
2017	78	171	$33,006
2018	102	191	$28,996
2019	35	116	$13,184
2020	N/R	12	$1,317
2021	N/R	13	$1,188
2022	N/R	14	$570
2023	N/R	11	$1,109
2024	11	28	$2,373

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	95	283	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	222	$60
96372	Injection of drug or substance under skin or into muscle	40	323	$10
36415	Insertion of needle into vein for collection of blood sample	144	737	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	143	708	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	206	6,180	$2,807,574
Erleada	Apalutamide	169	5,070	$2,403,667
Imbruvica	Ibrutinib	102	2,864	$1,551,424
Kisqali	Ribociclib Succinate	108	2,989	$1,458,361
Lupron Depot	Leuprolide Acetate	224	19,352	$1,271,955

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	11	16	$2,171
K0001	Standard wheelchair	Y	N/R	12	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	161	$4,268	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eugenio Gerardo Galindo, M.D.?

Tedicare shows public-source Medicare data for Eugenio Gerardo Galindo, M.D. (NPI 1174599948), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eugenio Gerardo Galindo, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eugenio Gerardo Galindo, M.D.?

Eugenio Gerardo Galindo, M.D. is linked to MCALLEN ONCOLOGY PA (billing NPI 1982711743) in the available physician profile data.

Does Eugenio Gerardo Galindo, M.D. have Open Payments data?

Eugenio Gerardo Galindo, M.D. has 161 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.